相关实验视频

Updated: May 24, 2025

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

对于APOL1脏病的-葡萄糖共同载体抑制剂:呼吁进行研究

Baris Afsar¹, Rengin Elsurer Afsar², Yasar Caliskan^2,3

¹Department of Nephrology, Saint Louis University, School of Medicine, SSM Health Saint Louis University Hospital, Saint Louis, MO, USA. afsarbrs@yahoo.com.

International urology and nephrology

|March 4, 2025

概括

与脏疾病相关的阿波利波蛋白L1 (APOL1) 基因变异可能受益于-葡萄糖联合传输-2 (SGLT2) 抑制剂. 这些药物对APOL1介导的损伤具有潜在的保护作用.

科学领域:

遗传学是一个遗传学.
腎臟病學 (nephrology) 是一種醫學專業.
药理学药理学是指药理学的学科.

背景情况:

APOL1基因变异 (G1,G2) 能够保护人免受三虫病的感染,但却会导致脏疾病,特别是在撒哈拉以南非洲人群中.
APOL1诱导的损伤机制包括溶酶体/线粒体功能障碍,改变的自和免疫失调.
目前治疗APOL1病 (APOL1-KD) 的方法不足,需要新的治疗策略.

研究的目的:

审查-葡萄糖联合运输-2 (SGLT2) 抑制剂对APOL1病 (APOL1-KD) 的潜在益处.
基于它们在蛋白尿性脏疾病中的已知作用,探索SGLT2抑制剂的理论优势.

主要方法:

对APOL1-KD和SGLT2抑制机制的现有文献的审查.
分析SGLT2抑制剂作用与APOL1-KD病理生理学之间的潜在治疗重叠.

主要成果:

SGLT2 抑制剂表现出有益的作用,包括增加自然养,减少蛋白尿/蛋白质尿,改善线粒体功能.
这些药物具有抗氧化,抗炎和抗纤维性质.
理论上的好处表明SGLT2抑制剂可以减轻APOL1-KD的进展.

结论:

SGLT2 抑制剂为APOL1 脏疾病提供了一个有前途的治疗途径.
进一步的临床研究对于验证SGLT2抑制剂在APOL1-KD中的保护作用至关重要.

关键词:

这就是APOL1的原因.这是一种APOL1脏病.合唱性病是一种病.和葡萄糖联合运输抑制剂这就是Trypanosomiasis.

更多相关视频

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Published on: June 20, 2018

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

相关概念视频

Glucose Transporters

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Secondary Active Transport

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...